Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
50–85
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Have a diagnosis of dementia of the Alzheimer's type according to the DSM-IV criteria and have a clinical diagnosis of probable AD according to NINCDS/ADRDA criteria
MMSE score of ≥ 10 and ≤ 26
The treatment naïve patient and the one who have stopped the donepezil, galantamine, huperzine A, or memantine at least 2 weeks
Be in stable medical condition
Have signed off informed consent form by patients or his/her legal guardian
You may not be if
Severe AD
Patients with a history of cerebrovascular disease, Active or uncontrolled epilepsy, Active hypothyroidism, asthma, CNS infection, other Neurodegenerative disorders, an advanced, severe, progressive, or unstable medical condition
Attending other clinical trials or taking other clinical trial drugs
A score of \> 4 on the Modified Hachinski Ischemic Scale (MHIS);
